Sangamo Therapeutics, Inc.

( )
SGMO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. -3.21%137.710.0%$884.02m
AMGNAmgen, Inc. -0.57%243.961.5%$794.57m
GILDGilead Sciences, Inc. 0.06%63.221.0%$531.81m
VRTXVertex Pharmaceuticals, Inc. -3.62%252.351.9%$444.70m
REGNRegeneron Pharmaceuticals, Inc. -1.25%659.202.6%$412.80m
ILMNIllumina, Inc. -1.40%239.813.3%$302.05m
NVAXNovavax, Inc. 0.31%52.1175.7%$294.76m
BIIBBiogen, Inc. -3.54%195.711.8%$238.30m
BNTXBioNTech SE -1.72%157.060.0%$213.96m
SNSSSunesis Pharmaceuticals, Inc. -2.86%2.040.7%$142.60m
EXASEXACT Sciences Corp. -3.90%52.0017.7%$139.49m
NKTXNkarta, Inc. -5.29%13.080.0%$101.73m
TECHBio-Techne Corp. -3.22%359.094.5%$98.14m
BMRNBioMarin Pharmaceutical, Inc. -1.19%78.184.2%$97.71m
TXG10X Genomics, Inc. -4.31%47.330.0%$92.15m

Company Profile

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.